Results 81 to 90 of about 4,872,021 (285)

Editorial: Physiological and biomechanical determinants of swimming performance-volume 2. [PDF]

Front Sports Act Living, 2023
De Souza Castro F, Figueiredo P, Toubekis AG, Barbosa TM, McCabe C.   +4 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Full issue-- Volume 3 Issue 1, 2020

, 2020
PURSUE: Undergraduate Research Journal Volume 3 Issue 1, 2020 Article 1 - Harvesting Electrical Energy Produced by Electrogenic Bacteria in Microbial Fuel Cells Article 2 – The Effects of Fertilizer Rate on the Growth of Egyptian Spinach in a Greenhouse ...
Volume 3, Issue 1
core  

COVER

, 2013
Volume 9, No.2, Mei 2010 ISSN 1412 ...
Mei 2010 ISSN 1412-2782, Volume 9, No.2,
core   +3 more sources

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

DFU, Volume 2, Scientific Visualization: Interactions, Features, Metaphors, Complete Volume

, 2012
DFU, Volume 2, Scientific Visualization: Interactions, Features, Metaphors, Complete ...
Hagen, Hans
core   +1 more source

Editorial: Nanotechnology for Antimicrobials, Volume 2. [PDF]

Front Microbiol, 2022
Nakazato G, Kobayashi RKT.
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Editorial: Advances and Challenges of RNAi Based Technologies for Plants-Volume 2. [PDF]

Front Plant Sci, 2022
Mezzetti B, Arpaia S, Baraldi E, Dietz-Pfeilstetter A, Smagghe G, Ventura V, Sweet JB.   +6 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source